UK markets closed

Silence Therapeutics plc (SLNCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
29.850.00 (0.00%)
As of 12:05PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.68B
Enterprise value 2.61B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)147.89
Price/book (mrq)555.92
Enterprise value/revenue 174.00
Enterprise value/EBITDA -57.12

Trading information

Stock price history

Beta (5Y monthly) 0.50
52-week change 3259.64%
S&P500 52-week change 3-5.84%
52-week high 329.85
52-week low 32.50
50-day moving average 35.70
200-day moving average 36.58

Share statistics

Avg vol (3-month) 345
Avg vol (10-day) 340
Shares outstanding 589.79M
Implied shares outstanding 6N/A
Float 822.34M
% held by insiders 156.74%
% held by institutions 127.76%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in GBP.

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin -257.95%
Operating margin (ttm)-305.44%

Management effectiveness

Return on assets (ttm)-30.93%
Return on equity (ttm)-592.75%

Income statement

Revenue (ttm)14.99M
Revenue per share (ttm)0.17
Quarterly revenue growth (yoy)82.00%
Gross profit (ttm)4.96M
EBITDA -45.56M
Net income avi to common (ttm)-38.67M
Diluted EPS (ttm)-0.53
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)59.3M
Total cash per share (mrq)0.66
Total debt (mrq)90k
Total debt/equity (mrq)2.26
Current ratio (mrq)4.89
Book value per share (mrq)0.04

Cash flow statement

Operating cash flow (ttm)4.52M
Levered free cash flow (ttm)-27.78M